These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 34567919)

  • 1. Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial.
    Sawano F; Kamei N; Miyahara M; Kobuke K; Nakanishi S; Nagano C; Nojima H; Maeda S; Watanabe H; Kishimoto R; Yamashita M; Hamaoka A; Mukai K; Tsuboi T; Mochizuki H; Nakashima R; Sakashita Y; Morishita H; Kitamura T
    Diabetol Int; 2021 Oct; 12(4):364-378. PubMed ID: 34567919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study.
    Ishihara H; Yamaguchi S; Nakao I; Asahina S; Sakatani T
    Diabetol Int; 2019 Jan; 10(1):37-50. PubMed ID: 30800562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).
    Sugawara M; Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K;
    Diabetes Ther; 2023 Sep; 14(9):1517-1535. PubMed ID: 37410308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
    Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Feb; 8(2):116-25. PubMed ID: 26767080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.
    Ishihara H; Yamaguchi S; Nakao I; Sakatani T
    Diabetes Ther; 2018 Aug; 9(4):1549-1567. PubMed ID: 29926400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
    Kutoh E; Murayama T; Wada A; Hirate M
    Drugs R D; 2016 Dec; 16(4):369-376. PubMed ID: 27798769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
    Iemitsu K; Kawata T; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Sep; 9(9):793-801. PubMed ID: 28811858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus.
    Kashiwagi A; Kazuta K; Yoshida S; Nagase I
    J Diabetes Investig; 2014 Jul; 5(4):382-91. PubMed ID: 25411597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor.
    Kusunoki M; Sato D; Sakazaki T; Miyata T; Tsutsumi K; Oshida Y
    Drug Res (Stuttg); 2020 Apr; 70(4):131-136. PubMed ID: 32164029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study.
    Koshizaka M; Ishikawa K; Ishibashi R; Takahashi S; Sakamoto K; Yokoh H; Baba Y; Ide S; Ide K; Ishikawa T; Onishi S; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Maezawa Y; Yokote K
    Diabetes Ther; 2021 Jan; 12(1):183-196. PubMed ID: 33098565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice.
    Terasaki M; Hiromura M; Mori Y; Kohashi K; Kushima H; Ohara M; Watanabe T; Andersson O; Hirano T
    Int J Endocrinol; 2017; 2017():1365209. PubMed ID: 28408925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
    Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
    BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
    Kawata T; Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Jul; 9(7):586-595. PubMed ID: 28611859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K; Nishie W; Beniko M; Shimizu H
    Front Immunol; 2019; 10():1439. PubMed ID: 31297116
    [No Abstract]   [Full Text] [Related]  

  • 17. Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study).
    Hashimoto-Kameda R; Cho KY; Nomoto H; Nakamura A; Omori K; Nagai S; Edagawa S; Kawata S; Takeuchi J; Kameda H; Kurihara Y; Aoki S; Atsumi T; Miyoshi H;
    Diabetes Res Clin Pract; 2021 Oct; 180():109069. PubMed ID: 34563585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
    Okajima F; Nagamine T; Nakamura Y; Hattori N; Sugihara H; Emoto N
    J Diabetes Investig; 2017 May; 8(3):341-345. PubMed ID: 27762088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study.
    Odawara M; Aoi S; Takeshima T; Iwasaki K
    Diabetes Ther; 2021 Aug; 12(8):2165-2177. PubMed ID: 34218420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.